Time-Course of the Effects of QSYQ in Promoting Heart Function in Ameroid Constrictor-Induced Myocardial Ischemia Pigs

Table 1

The comparison of echocardiography assessment of left ventricular function at each time point in each group (𝑥±𝑠).

Time	Group	𝑛	LVSV mL	ΔLVSV mL	LVDV mL	ΔLVDV mL	EF%	ΔEF%
Before administration	Sham	4	6.51±2.40	—	26.70±8.27	—	76.93±4.22	—
	Model	6	20.05±2.08^∗	—	43.18±4.08	—	51.85±7.50^∗∗	—
	Digoxin	6	27.53±12.97^∗∗	—	51.73±21.38^∗	—	47.90±14.07^∗∗	—
	QSYQ	6	29.30±7.93^∗∗	—	46.77±11.41^∗	—	36.90±12.70^∗∗	—
2 weeks after administration	Sham	4	5.76±1.83	−0.75±0.57	25.20±4.06	−1.50±12.33	77.68±3.33	0.75±0.89
	Model	6	20.00±5.04^∗	−0.05±2.963	39.40±12.15	−3.78±8.07	46.05±7.55^∗∗	−5.80±0.05
	Digoxin	6	20.67±9.67^∗	−6.86±3.30^∗▵▵	46.00±15.30^∗	−5.73±6.08	56.78±15.04^∗∗	8.88±0.97^∗∗▵▵
	QSYQ	6	25.53±5.78^∗	−3.77±2.15	47.97±7.82	1.20±3.59	47.13±3.99^∗∗	10.23±8.71^▵▵▴
4 weeks after administration	Sham group	4	6.77±2.85	0.26±0.45	30.63±7.12	3.93±15.39	79.05±5.61	10.23±9.78
	Model group	6	22.85±5.31^∗∗	2.80±3.23	50.08±11.76^∗	6.90±7.68	50.34±7.44^∗∗	−1.51±0.06
	Digoxin group	6	20.83±9.22^∗	−6.70±3.75^∗▵▵	44.95±12.43	−6.78±8.95^∗∗▵▵	55.23±15.95^∗∗	7.33±1.88^∗∗▵▵
	QSYQ	6	20.67±12.65^∗	−8.63±4.72^▵	44.97±21.84	−1.80±10.43^∗∗▵▵	55.80±8.23^∗∗	18.90±4.47^∗▵▵▴▴
8 weeks after administration	Sham group	4	7.10±3.18	0.59±0.78	28.98±6.98	2.28±15.25	74.88±6.84	18.90±12.03
	Model group	6	21.88±7.65^∗∗	1.83±5.57	46.88±13.52^∗	3.70±9.44	50.71±8.97^∗∗	−1.14±1.47
	Digoxin group	6	18.03±6.20^∗	−9.50±6.77^∗∗▵▵	42.75±7.67	−8.98±13.71	53.98±14.74^∗∗	6.08±0.67^∗∗▵▵
	QSYQ	6	17.81±8.49	−11.49±0.56^∗∗▵▵	30.07±10.09	−16.70±1.32^∗∗▵▵	55.87±5.02^∗	18.97±7.68^∗∗▵▵▴▴

Note: ^∗𝑃<0.05 and ^∗∗𝑃<0.01 compared with sham group; ^▵𝑃<0.05 and ^▵▵𝑃<0.01 compared with model control group; and ^▴𝑃<0.05 and ^▴▴𝑃<0.01 compared with digoxin group.
ΔLVSV = LVSV_𝑡  −  LVSV _{before administration}, ΔLVDV = LVDV_𝑡  −  LVDV _{before administration}, and ΔEF% = EF%_𝑡  −  EF% _{before administration}.